Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11400720 | 0.81 | MMP1 (0.52) | TSHRMMP1MMP2MMP3MMP9 | |
| SCHEMBL13312890 | 0.75 | TSHR (0.43) | TSHRALDH1A1TDP1 | |
| SCHEMBL18039277 | 0.75 | MMP1 (0.45) | TSHRMMP1MMP2MMP3MMP9 | |
| SCHEMBL5718402 | 0.75 | MMP1 (0.45) | TSHRMMP1MMP2MMP3MMP9 | |
| SCHEMBL18716512 | 0.74 | MMP1 (0.32) | MMP1MMP2MMP3MMP9MMP13 | |
| SCHEMBL15116682 | 0.69 | — | — | |
| SCHEMBL13611203 | 0.69 | — | — | |
| Acetic Acid SCHEMBL28618490 | 0.68 | TSHR (0.41) | TSHRALDH1A1TDP1 | |
| SCHEMBL3979990 | 0.68 | PGD (0.42) | TSHRMMP1MMP2MMP3MMP9 | |
| SCHEMBL13554083 | 0.67 | TSHR (0.39) | TSHRMMP1MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546388-B2 | Heterocyclic TRPV1 receptor ligands | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | PURDUE PHARMA L.P. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137306-A1 | HETEROCYCLIC TRPV1 RECEPTOR LIGANDS | TRPV1, TRPA1, TRPV2 | TSHR 2214/4885MMP1 3152/4885MMP2 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.